Cisplatin

Platinum-Based Antineoplastic — Oncology

• Drug Class: Platinum-Based Antineoplastic
• Category: Oncology
• Type: Small Molecule
• SMILES: N.N.Cl[Pt]Cl

What is Cisplatin?

Cisplatin is a cornerstone chemotherapy drug widely utilized in the fight against various cancers. As a platinum-based antineoplastic agent, it plays a crucial role in regimens aimed at eradicating or controlling malignant tumors. Developed in the 1960s, its efficacy has made it indispensable in modern oncology. While often referred to by its generic name, Cisplatin, it is also available under various brand names, with Platinol being a prominent example. Its therapeutic impact stems from its ability to interact with cellular DNA, ultimately leading to the death of rapidly dividing cancer cells. This section will delve into the fundamental aspects of Cisplatin, setting the stage for a deeper understanding of its complex role in cancer therapy.

Mechanism of Action

The potent anti-cancer activity of Cisplatin is intricately linked to its interaction with cellular DNA. Once administered, Cisplatin enters cells, where the chloride ligands are displaced by water molecules in an aquation process. This aquated form, a positively charged platinum complex, is highly reactive and readily binds to nucleophilic sites on DNA, particularly the N7 position of guanine bases.

DNA Adduct Formation

Cisplatin primarily forms intrastrand cross-links, connecting adjacent purine bases (guanine-guanine or guanine-adenine) on the same DNA strand. It can also form interstrand cross-links, connecting bases on opposite DNA strands, and DNA-protein cross-links. These adducts distort the DNA helix structure, interfering with critical cellular processes such as DNA replication and transcription.

Cellular Response to DNA Damage

The DNA damage induced by Cisplatin triggers various cellular responses. DNA repair mechanisms attempt to correct the adducts, but if the damage is too extensive or the repair is faulty, the cell initiates programmed cell death, or apoptosis. Cancer cells, with their rapid proliferation and often compromised DNA repair pathways, are particularly susceptible to this mechanism. The precise signaling pathways involved include the activation of p53, the induction of cell cycle arrest, and the activation of apoptotic cascade proteins. While Cisplatin targets rapidly dividing cells, it can also affect healthy, rapidly dividing cells, leading to its characteristic side effects. The selectivity for cancer cells is not absolute, highlighting the challenges in optimizing chemotherapy regimens.

Clinical Uses & Indications

Cisplatin is a versatile chemotherapeutic agent approved by the U.S. Food and Drug Administration (FDA) for the treatment of a wide spectrum of solid tumors. Its efficacy has established it as a first-line treatment option for many of these malignancies, often in combination with other chemotherapy drugs.

FDA-Approved Indications

• Testicular Cancer: Cisplatin is a cornerstone in the treatment of advanced testicular cancer, significantly improving cure rates.
• Ovarian Cancer: It is used in the management of advanced ovarian cancer, often in combination with other agents.
• Bladder Cancer: Cisplatin-based chemotherapy is a standard treatment for invasive bladder cancer.
• Lung Cancer: It is employed in the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
• Head and Neck Cancers: Cisplatin is a key component in the treatment of squamous cell carcinomas of the head and neck.
• Cervical Cancer: It is used in the treatment of advanced cervical cancer.
• Other Cancers: Cisplatin may also be used in the treatment of other cancers, including endometrial cancer, esophageal cancer, and osteosarcoma, often in specific clinical scenarios or as part of investigational protocols.

The choice of Cisplatin and its dosage is highly dependent on the type and stage of cancer, the patient's overall health, and the presence of other medical conditions. It is frequently administered in cycles, with periods of treatment followed by rest periods to allow the body to recover from the effects of the drug.

Dosage & Administration

The dosage and administration of Cisplatin are critical components of its therapeutic use, requiring careful calculation and monitoring to maximize efficacy while minimizing toxicity. Due to its potent nature and potential for severe side effects, Cisplatin is administered by healthcare professionals trained in the use of cytotoxic agents.

Common Dosage Forms and Routes

Cisplatin is typically available as a sterile powder for solution or a ready-to-use solution for intravenous (IV) infusion.

• Intravenous Infusion: This is the primary route of administration. Cisplatin is diluted in a suitable IV fluid, such as 0.9% sodium chloride or 5% dextrose in water, and infused slowly over a period of several hours. The duration of infusion can vary, but it is often administered over 6 to 8 hours, or sometimes longer, depending on the specific protocol and patient tolerance.

Factors Influencing Dosage

Dosage is highly individualized and determined by several factors:

• Body Surface Area (BSA): Dosing is frequently calculated based on the patient's BSA, which is a measure that correlates with metabolic mass.
• Type and Stage of Cancer: Different cancers and stages of disease require varying doses and treatment schedules.
• Renal Function: Kidney function is a critical determinant of Cisplatin dosage, as the drug is primarily eliminated by the kidneys. Pre-hydration and careful monitoring of renal function are essential.
• Hepatic Function: Liver function may also influence dosage adjustments.
• Previous Chemotherapy and Concurrent Medications: Prior treatments and other drugs being taken can affect how Cisplatin is tolerated and dosed.

Pre- and Post-Hydration

Aggressive hydration with intravenous fluids is a standard practice before, during, and after Cisplatin administration. This helps to promote diuresis, facilitate renal excretion of the drug and its metabolites, and reduce the risk of nephrotoxicity. Mannitol or other diuretics may also be administered to enhance urine output. Patients are typically advised to drink plenty of fluids orally as well.

Monitoring

Close monitoring of blood counts, electrolytes, renal function (serum creatinine, BUN, creatinine clearance), and liver function is essential throughout the treatment course.

Side Effects & Safety

While Cisplatin is a powerful tool against cancer, its administration is associated with a range of potential side effects, some of which can be severe. Understanding these effects and implementing appropriate management strategies are crucial for patient safety and treatment tolerance.

Common Side Effects

• Nausea and Vomiting: This is one of the most frequent and often severe side effects. Antiemetic medications are routinely administered to manage this.
• Nephrotoxicity (Kidney Damage): Cisplatin can cause significant kidney damage, manifesting as decreased urine output, elevated blood urea nitrogen (BUN), and serum creatinine. Aggressive hydration is key to prevention.
• Ototoxicity (Hearing Damage): This can include tinnitus (ringing in the ears) and hearing loss, which may be irreversible.
• Peripheral Neuropathy: Numbness, tingling, and pain in the hands and feet can occur, often progressing with cumulative dose.
• Myelosuppression: Reduced production of blood cells, leading to anemia (low red blood cells), leukopenia (low white blood cells, increasing infection risk), and thrombocytopenia (low platelets, increasing bleeding risk).
• Electrolyte Imbalances: Hypomagnesemia (low magnesium), hypokalemia (low potassium), and hypocalcemia (low calcium) can occur.
• Fatigue: Profound tiredness is common.
• Alopecia (Hair Loss): While not as common or severe as with some other chemotherapies, hair thinning or loss can occur.

Serious and Less Common Side Effects

• Anaphylactic-like Reactions: Rare but serious hypersensitivity reactions can occur, particularly during rapid infusion.
• Hepatotoxicity (Liver Damage): Less common than nephrotoxicity but can occur.
• Cardiotoxicity: Although rare, cardiac events have been reported.
• Secondary Malignancies: As with many chemotherapies, there is a potential long-term risk of developing secondary cancers.

Contraindications and Precautions

Cisplatin is contraindicated in patients with:

• Known hypersensitivity to Cisplatin or other platinum-containing compounds.
• Severe myelosuppression.
• Severe renal impairment.
• Severe hearing impairment.

Precautions should be taken in patients with:

• Pre-existing renal or hepatic disease.
• Pre-existing neurological conditions.
• Pre-existing hearing deficits.
• Concurrent use of nephrotoxic agents.

Regular monitoring of kidney function, hearing, and neurological status is essential for patients receiving Cisplatin.

Drug Interactions

Cisplatin has the potential to interact with a variety of other medications, which can alter its efficacy, increase its toxicity, or affect the metabolism and excretion of the interacting drug. Careful consideration of concomitant medications is vital when prescribing Cisplatin.

Notable Drug Interactions

• Nephrotoxic Agents: Concomitant use with other drugs known to cause kidney damage, such as aminoglycosides (e.g., gentamicin, tobramycin), amphotericin B, and certain radiocontrast agents, can significantly increase the risk and severity of nephrotoxicity. Careful monitoring of renal function is paramount.
• Ototoxic Agents: Combining Cisplatin with other ototoxic drugs, like aminoglycosides or loop diuretics (e.g., furosemide), can potentiate hearing loss and tinnitus.
• Myelosuppressive Agents: Concurrent administration with other chemotherapy drugs or agents that suppress bone marrow (e.g., anthracyclines, cyclophosphamide) can lead to additive myelosuppression, increasing the risk of infection and bleeding.
• Live Vaccines: Patients receiving chemotherapy, including Cisplatin, generally should not receive live attenuated vaccines due to the risk of disseminated infection.
• Anticonvulsants: Cisplatin may decrease the serum levels of certain anticonvulsant medications, such as phenytoin, potentially leading to loss of seizure control.
• Fluorouracil (5-FU): Some studies suggest a potential for increased toxicity when used concurrently, although combination therapy is common in certain settings.
• Neupogen (Filgrastim) and Neulasta (Pegfilgrastim): While these colony-stimulating factors are often used to mitigate neutropenia caused by chemotherapy, their use in conjunction with Cisplatin requires careful timing and consideration.

It is imperative for healthcare providers to review a patient's complete medication list, including over-the-counter drugs and herbal supplements, before initiating Cisplatin therapy and to monitor for potential interactions throughout treatment.

Molecular Properties

Understanding the molecular properties of Cisplatin is fundamental to comprehending its chemical behavior, interactions, and formulation. These characteristics dictate how the drug functions at a cellular level and how it is handled within the body.

Key Molecular Data

Molecular Formula:	Cl2H6N2Pt
Molecular Weight:	300.04 g/mol
Structure Description:	Cisplatin is a square planar coordination complex. It features a central platinum (Pt) atom bonded to two chloride (Cl) ligands and two ammonia (NH3) ligands. The key feature is that the two ammonia ligands are positioned adjacent (in a cis configuration) to each other, and similarly, the two chloride ligands are also adjacent. This specific spatial arrangement is crucial for its biological activity. The SMILES notation provides a linear representation of this molecular structure.
SMILES Notation:	N.N.Cl[Pt]Cl

Description of SMILES Notation: N.N.Cl[Pt]Cl

The SMILES (Simplified Molecular Input Line Entry System) string N.N.Cl[Pt]Cl is a compact way to represent the structure of Cisplatin. Let's break it down:

• Pt represents the central Platinum atom.
• Cl represents a Chlorine atom.
• N represents a Nitrogen atom, which in this context forms part of an ammonia ligand (NH₃). The SMILES notation simplifies this by just showing the atom.
• The dots (.) between N and N, and between N and Cl[Pt]Cl, indicate separate atoms or groups that are bonded to the central atom. In this simplified representation, the SMILES string implies that the two 'N' atoms (from the ammonia ligands) and the two 'Cl' atoms (chloride ligands) are all directly bonded to the central 'Pt' atom. The 'cis' configuration, meaning adjacent placement, is implied by the overall connectivity described by the SMILES string in conjunction with the known structure of Cisplatin.

This molecular architecture allows Cisplatin to readily undergo aquation in biological fluids and subsequently bind to DNA, initiating its cytotoxic effects.

Analyze Cisplatin with MolForge

Understanding the intricate molecular mechanisms, clinical applications, and potential interactions of drugs like Cisplatin is paramount in pharmaceutical research and development. MolForge's AI-powered platform offers advanced tools to explore these complex molecules in unprecedented detail. By leveraging our sophisticated algorithms, researchers can delve into Cisplatin's structure, predict its binding affinities, analyze its metabolic pathways, and investigate potential novel therapeutic applications or drug combinations. Whether you are optimizing existing chemotherapy regimens, searching for new platinum-based analogs, or understanding resistance mechanisms, MolForge provides the computational power to accelerate your discovery process. Explore the full potential of molecular analysis and drug discovery. Visit our dashboard today to begin your journey with MolForge AI.